More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a ...

More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

Asthma inhaler access dropped from nearly 41% to nearly 35% between 2021 and 2023 among patients 18 and younger prescribed Flovent (fluticasone), researchers found. By comparison, young asthma ...

Last year saw a key development in the US respiratory diseases market when Mylan finally launched its generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol).